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Abstract
Background Peripartum cardiomyopathy (PPCM) is an
idiopathic heart disease that develops in the last month of
pregnancy and/or the first months following delivery in
previously healthy women and may lead to acute heart
failure. A cleaved fragment of the nursing hormone pro-
lactin is considered essential in the pathophysiology of
PPCM. To date, no specific therapy has been tested for
PPCM in a randomized controlled trial of adequate size.
Aims The purpose of this trial is to investigate the safety of
the dopamin-D2-receptor agonist bromocriptine and its ef-
fects on left ventricular (LV) function in women with PPCM.
Methods This is an 11 center German trial with a
prospective randomized controlled open-label design. The
trial enrolls females with newly diagnosed PPCM accord-
ing to European Society of Cardiology criteria with a LV
ejection fraction (LVEF)\35 %. Patients are randomized
1:1 to either best supportive care (BSC) including standard
heart failure therapy plus 8 weeks of bromocriptine therapy
(2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to
56) or to BSC plus 1 week of low-dose bromocriptine
(2.5 mg q.d.) with anticoagulant therapy at a prophylactic
dose administered during the period of bromocriptine
treatment in both groups. The primary endpoint is change
in LVEF from baseline to 6 months follow-up as assessed
by cardiac magnetic resonance imaging (or echocar-
diography if CMR is not tolerated). The secondary end-
points are hospitalization for worsening heart failure, heart
transplantation, and all-cause mortality during follow-up or
a combination of these endpoints. A total of 60 patients
will be recruited (including 6 potential dropouts) giving a
power of 0.9 for an expected LVEF change of 10.8 %
between treatment groups at 6 months.
Perspective This trial will provide important knowledge
on potential benefits and safety of prolonged inhibition of
prolactin release with bromocriptine in addition to standard
heart failure therapy in newly diagnosed PPCM.
Trial registration: ClinicalTrials.gov Identifier:
NCT00998556.
Keywords Peripartum cardiomyopathy  Bromocriptine 
Prolactin  Heart failure
Introduction
Peripartum cardiomyopathy (PPCM) is an idiopathic car-
diomyopathy toward the end of pregnancy or in the months
following delivery presenting with acute heart failure with
reduced left ventricular (LV) function [1, 2]. The incidence
of PPCM ranges from 1:299 births in Haiti to about 1:1000
in South Africa and in the USA [2, 3].
Moreover, recent studies suggest a growing incidence of
PPCM [3] which may be partly due to certain socio-
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environmental factors that still need to be identified and
partly due to improved awareness to this disease and ad-
vances in diagnostic opportunities.
Although PPCM is presumed to be associated with a
higher likelihood of recovery of LV function than other
cardiomyopathies [4], we recently reported on 15 %
treatment failure in a German registry with prospective
data of 96 PPCM patients despite optimal medical therapy.
The disease is potentially life threatening with region-
ally varying mortality rates ranging between 2 % in our
registry under contemporary management concepts, and up
to 50 % in other studies [5–7].
Importantly, a number of studies on PPCM cohorts of
different ethnicities have demonstrated that the presence of
severe LV dysfunction at baseline is associated with a low
probability of full cardiac recovery [5, 8]. Among the trig-
gering factors the nursing hormone prolactin is considered to
play a key role in the pathophysiology of (PPCM). Under
circumstances of enhanced oxidative stress that typically
occurs toward the end of pregnancy and during delivery,
prolactin is increasingly cleaved into a 16 kDa fragment
(16 kDa PRL) under conditions of defective antioxidative
mechanisms [9]. The 16 kDa PRL is known to exert detri-
mental effects on themicrovasculature of the heart leading to
cardiac injury and dysfunction [9, 10].
Despite these advances in understanding the pathome-
chanisms of PPCM, clinical trials testing disease-specific
therapeutics still remain scarce. In fact, apart from standard
heart failure medication no specific therapy is available for
PPCM to date.
Thus, there is a need for new therapeutic strategies to
counteract the detrimental pathomechanisms in PPCM and
enhance myocardial recovery. Given the key role of pro-
lactin in the pathogenesis of PPCM, prolonged inhibition of
prolactin release by the dopamin-D2-receptor agonist bro-
mocriptine may represent one therapeutic opportunity. After
this approach had been successfully tested in single cases
[11], a prospective, single-center, randomized, open-label,
pilot study of African women with newly diagnosed PPCM
was performed which compared standard heart failure care
in PPCM patients versus standard care plus treatment with
bromocriptine for 8 weeks with 10 patients per group
(Table 1) [12].
Patients receiving bromocriptine displayed greater re-
covery of ejection fraction at 6 months andwere less likely to
experience the composite end point of poor outcome defined
as death, New York Heart Association (NYHA) functional
class III/IV, or left ventricular ejection fraction\35 % at
6 months than the patients receiving standard care. One
patient in the bromocriptine group died compared with 4
patients in the standard care group. Although of limited small
size, this trial justified the concept of targeting prolactin as a
novel therapeutic strategy for PPCM and provided the ra-
tionale for a larger randomized and controlled clinical trial
with bromocriptine (Table 1). This concept was further
supported by the results of the German PPCM registry [5]
demonstrating cardiac improvement in 96 % of the patients
receiving bromocriptine in a non-randomized manner in
addition to a beta-blocker and angiotensin-converting en-
zyme (ACE-) inhibitors (Table 1).
Thus, the objective of the present study is to determine
in a randomized and controlled design and with adequate
sample size the therapeutic potential and safety of bro-
mocriptine in patients with acute heart failure and reduced
LV function due to newly diagnosed PPCM.
Study design
This study is a prospective, randomized, controlled trial,
which is conducted in 11 centres in Germany (Fig. 1).
Eligibility
The inclusion and exclusion criteria are summarized in
Table 2. The aim is to enroll patients with newly diagnosed
PPCM in accordance to the definition proposed by the
Working Group on PPCM from the Heart Failure Asso-
ciation of the European Society of Cardiology (ESC) [1]
which is as follows: (a) evidence of heart failure secondary
to systolic dysfunction toward the end of pregnancy or in
the months following delivery, where no other cause of
heart failure is found; (b) it is a diagnosis of exclusion;
(c) the left ventricle may not be dilated but the ejection
fraction is nearly always reduced below 45 %.
Specific inclusion criteria include (1) the confirmed di-
agnosis of new onset PPCM within a time-window of
5 months postpartum; (2) LV ejection fraction (LVEF)
below 35 % as assessed by echocardiography; (3) the age
of 18 years or older; and (4) the ability to give written
informed consent. PPCM is defined as a non-familial form
Table 1 Summary of published studies investigating bromocriptine in patients with PPCM
Study Sample size (n) Treatment duration Randomized? Controlled? Endpoint
Sliwa et al. [12] 20 8 weeks Yes Yes LVEF at 6-month follow-up
Haghikia et al. [5] 96 4 weeks No No LVEF at 6-month follow-up
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of peripartum heart failure characterized as an ‘‘idiopathic
cardiomyopathy presenting with heart failure secondary to
left ventricular (LV) systolic dysfunction towards the end
of pregnancy or in the months following delivery, where no




Potential participants are all women with PPCM in the first
5 months postpartum displaying clinical signs of heart
failure. After explanation of the nature and scope of the
study and a sufficient period of reflection, the investigator
must obtain the informed consent by means of a standard
written statement in non-technical language. Patients may
withdraw their consent of participation at any time of the
trial without providing a reason. Patients with heart failure
symptoms are screened for PPCM by echocardiography
and further inclusion and exclusion criteria are evaluated
during the enrolment and randomization visit (visit 1).
Enrolment and randomization (visit 1)
At visit 1, patient eligibility is evaluated based on the in-
clusion/exclusion criteria (Table 2). If the patient is con-
sidered eligible, the medical history is assessed, physical
examination, ECG, and echocardiography are performed
and the NYHA class and vital signs are documented. The
baseline LVEF has to be determined by cardiac magnetic
resonance imaging (CMR) within 5 days after beginning of
bromocriptine therapy. Alternatively, if the patient does not
tolerate CMR or CMR is temporarily not available, it may as
an exception be replaced by two separate echocardiograms
with determination of the LVEFs (Simpson’s method) by
two independent investigators blinded to each others results.
Moreover, laboratory tests for NTproBNP, hemoglobin,
serum sodium and potassium, glucose, aspartate amino-
transferase, alanine aminotransferase, total bilirubin, blood
urea, nitrogen, and serum creatinine are measured. The
quality of life is assessed by means of a questionnaire.
Patients who are not eligible to participate in the study
are asked to provide their demographic (age, parity, ethnic
background) and clinical data for the German PPCM reg-
istry [5] and the international registry on PPCM, which is
part of the ESC EURObservational Research Programme
(http://www.eorp.org) [13].
A central computerized randomization (modified ac-
cording to Pocock 15 and Pocock and Simon 16) of patients
fulfilling the inclusion criteria is performed at the Coordi-
nation Centre for Clinical Trials at the University of Leipzig
(ZKSLeipzig KKS). Patients are randomized in a 1:1 ratio to
either the treatment group or the control group. The treat-
ment group receives bromocriptine therapy at a dose of
2.5 mg b.i.d for the first 2 weeks and 2.5 mg o.d. for another
6 weeks (total treatment of 8 weeks with bromocriptine).
The control group receives low-dose bromocriptine
(2.5 mg o.d.) for up to 1 week to stop lactation. In both
* Anticoagulation therapy at prophylactic dose is administered during treatment with 
bromocriptine. 
Signed informed consent 
      Screening 
New onset PPCM within 5 months post partum 
    Randomization 
1:1, n = 60 
•  Bromocriptine for 8 weeks *:  
 2.5 mg o.d. for remaining 6 weeks  
•  Standard heart failure therapy  
•
week *
•  Standard heart failure therapy  
                               Follow-up 
 Duration of follow-up: 6 months 
 Primary endpoint: Change in LVEF from baseline to 6 months follow-up
End-of-study 
Recording treatment and medical condition every 6 months until 
last patient out (end-of-
Fig. 1 Study design. Asterisks indicates anticoagulation therapy at
prophylactic dose is administered during treatment with
bromocriptine.
Table 2 Summarized inclusion and exclusion criteria







At least 18 years of age
Ability to give written
informed consent
Preexisting cardiac disease (except
PPCM with complete resolution)
Any preexisting serious conditions
Previous cardiac surgery or
percutaneous coronary intervention
History of alcohol and/or any other drug
abuse
Contraindication to the planned therapy
Concomitant therapy other than
specified in the trial protocol
Expected low compliance (e.g., by
travel distance to trial site)
Concomitant participation in other
clinical trials
ESC European Society of Cardiology, PPCM peripartum cardiomy-
opathy, LVEF left ventricular ejection fraction
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groups anticoagulant therapy at a prophylactic dose is ad-
ministered during the period of bromocriptine treatment to
prevent thrombotic side effects of bromocriptine.
Both groups are additionally treated with standard heart
failure medication as per current guidelines [14–17].
Specifically, this therapy includes ACE inhibitors or An-
giotensin II receptor blockers (ARBs), beta-blockers, min-
eralocorticoid receptor blockers (MRAs), diuretics, and
ivabradine if indicated. In addition, prolactin, NT-pro-BNP,
and a set of additional biomarkers for cardiovascular disease,
inflammation, and markers specific for the pathophysiology
of PPCM will be measured at each visit. Additionally, novel
potential biomarkers derived from experimental studies in
ongoing PPCM research in our and other labs will be tested
for diagnostic accuracy and prognostic value.
Monitoring of safety and tolerability and follow-up
(visits 2–4)
After enrolment, 3 study visits take place during a follow-
up period of 6 months: Visit 2 at week 2, visit 3 at week 4,
and visit 4 at the end of week 8. At each visit the medical
history and quality of life are assessed, and adverse events
(AEs) and serious adverse events (SAE) are documented.
Further, NYHA class and vital signs are documented and
physical examination, ECG, echocardiography, and
laboratory tests are performed. The compliance to study
medication is assessed and the standard heart failure
medication is adjusted if necessary.
End of follow-up at month 6 (visit 5)
At visit 5 the 6 months LVEF is determined by CMR. This
visit also includes all procedures performed at the previous
visits. The end of study is specified as the visit 5 of the last
patient. Until then the treatment and medical conditions of
the other patients are recorded every 6 months.
Study objectives
Primary objectives
The purpose of the study is to evaluate the effect of pro-
longed blockade of prolactin with bromocriptine on left
ventricular function in women with PPCM. The primary
endpoint is the change of LVEF from baseline to 6 months
follow-up determined at by CMR (Table 3).
Secondary objectives
The secondary endpoints are rate of hospitalizations for
worsening heart failure, heart transplantation, and mortality
during 6 months follow-up and the combination of the
afore mentioned endpoints (Table 3).
Statistical consideration
The estimated average change of LVEF during 6 months
for the primary endpoint was based on the previous pilot
study including 10 patients with and 10 patients without
bromocriptine where the average change of LVEF during
6 months was by absolute 23 % higher in the group with
bromocriptine [12]. We assume that the average difference
between the groups in this study is 12 % absolute, corre-
sponding to a 52 % relative reduction of the effect seen in
the pilot study. If we assume that the patients in the control
group who receive 1/10 of the cumulative dose given to the
patients of the treatment group might have 1/10 of the
benefit, this will reduce the average gain in LVEF to 10.8 %
in absolute terms with a standard variation of 12 %. Con-
sequently, to detect this difference in a two-sided difference
test with a type I error level of 0.05 and a power of 0.9, a
total of 54 patients is needed, 27 per group. Therefore, a
total of 60 patients (30 per group) should be sufficient to
allow for 3 dropouts per group. Regarding the primary
endpoint, an analysis of covariance will be performed. The
follow-up LVEF will be defined as dependent variable, the
treatment group as fixed factor and the baseline LVEF as
covariate. As for the secondary endpoints, frequency tables
of rates with appropriate 95 % confidence intervals will be
performed and comparisons using contingency tables will
be compiled. If sufficient numbers of events occur, addi-
tional time-to-event analyses, such as Kaplan–Meier esti-
mates of survival curves, will be carried out.
A final detailed plan for the statistical analyses will be
developed prior to the end of study and the start of the final
analysis.
Study duration, interim analyses, and early
termination
The expected total duration of this study is 60 months. The
estimated start of data cleaning is scheduled for July, 2016.
Table 3 Pre-specified endpoints
Primary endpoint Secondary endpoints
Change in LVEF from
baseline to 6 months
follow-up
Hospitalization for heart failure
symptoms during 6 months follow-
up
Necessity of heart transplantation
during 6 months follow-up
Mortality during 6 months follow-up
Combination of hospitalization, heart
transplantation, and mortality
during 6 months follow-up
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Given the rather small sample size, there will be no interim
analysis. Therefore, early termination due to putative sta-
tistically significant interim results will not occur.
Current status
To date, the protocol was approved by the Ethics Com-
mittee and the competent federal authority (BfArm). The
study is being conducted in accordance with the Declara-
tion of Helsinki (Version Somerset West 1996), German
laws and the ICH guidelines for Good Clinical Practice
(GCP). The trial has been registered on ClinicalTrials.gov,
NCT00998556. Patients started enrolling in this trial on 30
June 2010. As of October 2014, 108 patients have been
screened in 10 trial centres, of whom 49 patients have been
enrolled. Of the remaining 59 patients, 10 patients have
denied study participation, and 49 patients did not meet the
inclusion criteria. So far, 6 patients have dropped out after
randomization, of whom 5 patients were randomized to the
control group but wished to receive the bromocriptine
therapy according to the treatment, and one patient lost
contact to the study centre. Although the analysis of the
primary endpoint will be performed according to the in-
tention-to-treat principle, additional per protocol analyses
are also planned which will not be used for hypothesis
calculations but will serve to estimate and discuss potential
biases of the intention-to-treat analysis.
Safety considerations
Bromocriptine is a dopamine receptor agonist, available on
the market for many years, and indicated for treatment of
hyperprolactinemia-associated dysfunctions, acromegaly,
and Parkinson’s disease. In the postpartum phase, bromo-
criptine has been used worldwide since 1980 to suppress
lactation. The side effects of bromocriptine are well-known
[18] and include nausea, headache, dizziness, fatigue,
lightheadedness, vomiting, abdominal cramps, nasal con-
gestion, constipation, diarrhea, and drowsiness. Some
concerns have been raised about a potential risk for cere-
bral and cardiovascular complications, as emphasized in
some case reports describing stroke and coronary artery
thrombosis [19, 20], features that may be more associated
with the use of higher dose of bromocriptine. In our study,
we use low-dose bromocriptine of 2.5–5 mg/day and
specific attention is paid to ensure sufficient prophylactic
anticoagulant therapy during treatment with bromocriptine
as the procoagulatory activity in the peripartum phase ap-
pears to be increased [21]. Recently a review of the
available data on safety and effectiveness of bromocriptine
in controlling breast milk production after childbirth by the
Coordination Group for Mutual Recognition and Decen-
tralised Procedures—Human (CMDh) led to the conclusion
that bromocriptine should not be used routinely for pre-
venting or stopping milk production, and must not be used
in women at increased risk of serious side effects including
women with various disorders that increase blood pressure
or who have or have had heart disease or severe psychiatric
disorders. Following this recommendation, the European
Medicines Agency (EMA) endorsed the restricted use of
bromocriptine for stopping milk production on August 21st
2014.
However, this endorsement does not reflect the findings
of the German PPCM registry [5], the ESC PPCM registry
[13] or the safety data of this trial so far. The data of the
PPCM registry showed that almost all patients, 96 % (55/
57), who underwent a treatment combination of beta-
blockers, ACE inhibitors/angiotensin receptor blockers,
and bromocriptine under prophylactic anticoagulation im-
proved their condition without any incidence of bromo-
criptine-associated side effects In particular, no abnormally
high blood pressures or psychiatric disorders were ob-
served. The ESC PPCM registry has already enrolled over
200 cases, of whom 75 were treated with bromocriptine on
top of heart failure medication. In none of them a bromo-
criptine-elated adverse event was reported [13]. Thus, we
strongly favor the concept that in patients with PPCM low-
dose bromocriptine therapy as given in our study (and also
by many physicians as an individual treatment approach) is
justified despite the concerns put forward in the EMA
document. Based on the afore mentioned data the Study
Group on Peripartum Cardiomyopathy of the Heart Failure
Association of the European Society of Cardiology has
requested the revision of the endorsement by the EMA and
the permission for application of bromocriptine in PPCM
patients under close medical supervision.
Discussion
The results of this prospective, multicentre, randomized,
open-label study will allow to determine whether bromo-
criptine on top of standard heart failure medication leads to
improvement of LV function after 6 months in women
with PPCM. In a very recent nationwide population-based
study in the USA, the incidence and outcomes of PPCM
were investigated in detail [3]. The authors demonstrated
an increase of the incidence rate of PPCM, from 8.5 per
10,000 life births in 2011 to 11.8 per 10,000 life births in
2014. Importantly, the rate of maternal major adverse
events defined as cardiac arrest, heart transplant, me-
chanical circulatory support, acute pulmonary edema,
thromboembolism, or implantable cardioverter defibrilla-
tor/permanent pacemaker implantation increased from
11.7 % in 2004 to 15 % in 2011. Similar trends were ob-
served for in-hospital mortality with an increase from
Clin Res Cardiol (2015) 104:911–917 915
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0.7 % in 2004 to 1.3 % in 2011. These data demonstrate
that despite advances in medical care in Western societies
during the last decade, the treatment concepts so far have
failed to achieve improvements of the overall prognosis of
PPCM patients. Therefore, with the rising incidence of
PPCM and unaltered prognosis and lack of disease-specific
therapeutics, there is an urgent need for novel therapeutic
strategies [22]. This study is the first of this kind, and its
results may contribute to the development of therapeutic
strategies for the management of PPCM [3, 22].
The design of this study has been encouraged by a
previous pilot study [12] and the findings of the non-ran-
domized German PPCM registry [5] indicating beneficial
effects of bromocriptine on LV function in PPCM. How-
ever, the current study is not fully comparable with the
study be Sliwa et al. [12], which was placebo controlled as
opposed to our study which compares low-dose short-term
treatment of bromocriptine with prolonged bromocriptine
treatment. This study design was based on ethical concerns
about the continuation of lactation despite treatment of the
patients with heart failure medication with potential side
effects for the newborn, and because of the strong
therapeutic effect of bromocriptine in the pilot study.
Moreover, our ethic committee pointed out that stopping
lactation without offering medical support is not allowed in
Germany. The rationale for this treatment concept is based
on experimental and clinical observations that a cleaved
form of the nursing hormone prolactin, the 16 kDa pro-
lactin, plays a causal role in the development of PPCM [9,
12]. This cleaved peptide exerts strong angiotoxic effects,
in particular on the microvasculature, ultimately leading to
cardiomyocyte cell death, and fibrosis. This hypothesis is
supported by the evidence of increased serum levels of
16 kDa prolactin and augmented activity of the cleaving
enzyme, cathepsin D [5, 12], at baseline in PPCM patients
as compared to postpartal healthy women. Therefore, early
pharmacological blockade of prolactin with bromocriptine
may eliminate the detrimental effects of 16 kDa prolactin,
prevent damage of the microvasculature, cell death, and
replacement fibrosis, and thus, avoid adverse remodeling of
the diseased myocardium and improve cardiac function and
clinical condition of patients with acute onset of PPCM [9,
12]. Moreover, additional pleiotropic effects of bromo-
criptine are assumed to contribute to the healing process of
the injured myocardium in PPCM. For example, proin-
flammatory pathways are known to be involved in the
pathophysiology of PPCM [8, 23], which appear to be
modulated upon treatment with bromocriptine [9, 23].
Further studies are warranted to identify precise mechan-
isms by which bromocriptine modulates the immunological
responses that are activated in the development of PPCM.
Other beneficial effects that have been attributed to bro-
mocriptine are potential cytoprotective and antioxidative
capabilities that could compensate for defective antiox-
idative mechanisms proposed as an important patho-
physiological aspect in PPCM [8, 9]. Taken together, the
cardioprotective effects of bromocriptine are broader than
just effective prolactin blockade.
The basis of the dose and duration of bromocriptine
therapy in the present trial were previous observations in
animal models and case reports [11] which appeared to be
efficient in the pilot bromocriptine study [12]. The change
of LVEF was chosen as the primary endpoint as it is
suitable for relatively small sample sizes of rare diseases
such as PPCM.
Although blinding of the study is not possible due to
ethical concerns, the data analysis and assessment of out-
come is performed by blinded investigators which may
partly compensate for the unavoidable open-label design.
To date, the observations obtained from this study
indicate good safety and tolerability of bromocriptine in
PPCM patients. So far, none of the patients had to pre-
maturely terminate bromocriptine medication due to safety
concerns. In particular, no bromocriptine-associated
thrombotic complications were recorded. Only one patient
experienced an adverse event in terms of temporary nausea.
In summary, this study addresses the potential of bro-
mocriptine as add-on therapy in addition to standard heart
failure therapy to improve LV function in acute PPCM.
While initial results point to an adequate level of safety and
tolerability, final follow-up evaluation of all planned pa-
tients need to be awaited to definitely determine the effect
of bromocriptine on LV function in patients with acute
PPCM. The results of this trial may have decisive impact
on future management of PPCM patients.
Acknowledgments This trial is funded by the German Federal
Ministry of Education and Research (BMBF). Dr. Arash Haghikia
receives a scholarship from the ,,Junge Akademie‘‘ programme of
Hannover Medical School.
Manufacturer of the study drug: AbZ-Pharma GmbH.
Conflict of interest None of the member of the study team and
study committees has a conflict of interest or financial interest, ar-
rangement or affiliation with the manufacturer of the study drug.
Study management committees Sponsor and study coordination:
Authorized representative of the sponsor and study coordinator:
Denise Hilfiker-Kleiner (Hannover Medical School). Coordinating
clinical investigator: Johann Bauersachs (Hannover Medical School);
representative of the coordinating investigator: Arash Haghikia
(Hannover Medical School). Study management and biometry: The
creation of the study database, data management, drug safety and
biometry are coordinated by The Centre for Clinical Trials at the
University of Leipzig (ZKS Leipzig KKS). Safety monitoring board:
An independent, external data safety monitoring board (DSMB) has
been appointed to inspect the safety of the patients and review the
results of the annual safety reports (ASRs). The board members are:
John McMurray (University of Glasgow), Armin Koch (Hannover
Medical School), Gerd P. Meyer (Hannover) and Nikolaus Marx
(University of Aachen). Steering committee: Members of the Steering
916 Clin Res Cardiol (2015) 104:911–917
123
committee: Denise Hilfiker-Kleiner (chairperson, Hannover Medical
School), Johann Bauersachs (Hannover Medical School) and Michael
Bo¨hm (University of the Saarland). Clinical trial centres (local prin-
cipal investigators, PIs): Hannover Medical School (Johann Bauer-
sachs, Denise Hilfiker-Kleiner); Hospital of Nu¨rnberg (Johannes
Schwab); University Hospital of Du¨sseldorf (Ralf Westenfeld);
University Hospital of Heidelberg (Philipp Ehlermann); University
Hospital of Berlin, Charite Campus Mitte (Verena Stangl); University
Hospital of Berlin, Charite Campus Benjamin Franklin (Uwe Ku¨hl),
University Hospital of Cologne: (Roman Pfitzer), University Hospital
of Go¨ttingen (Rolf Wachter), University Hospital of Hamburg-Ep-
pendorf (Kai Muellerleile), University Hospital of Halle-Wittenberg
(Alexander Plehn); University Hospital of Saarland (Ingrid
Kindermann).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state
of knowledge on aetiology, diagnosis, management, and therapy
of peripartum cardiomyopathy: a position statement from the
Heart Failure Association of the European Society of Cardiology
Working Group on peripartum cardiomyopathy. Eur J Heart Fail
12:767–778
2. Sliwa K, Fett J, Elkayam U (2006) Peripartum cardiomyopathy.
Lancet 368:687–693
3. Kolte D, Khera S, Aronow WS et al (2014) Temporal trends in
incidence and outcomes of peripartum cardiomyopathy in the
United States: a nationwide population-based study. J Am Heart
Assoc 3:e001056
4. Felker GM, Thompson RE, Hare JM et al (2000) Underlying
causes and long-term survival in patients with initially unex-
plained cardiomyopathy. N Engl J Med 342:1077–1084
5. Haghikia A, Podewski E, Libhaber E et al (2013) Phenotyping
and outcome on contemporary management in a German cohort
of patients with peripartum cardiomyopathy. Basic Res Cardiol
108:366
6. Pearson GD, Veille JC, Rahimtoola S et al (2000) Peripartum
cardiomyopathy: National Heart, Lung, and Blood Institute and
Office of rare diseases (National Institutes of Health) workshop
recommendations and review. JAMA 283:1183–1188
7. Witlin AG, Mabie WC, Sibai BM (1997) Peripartum cardiomy-
opathy: a longitudinal echocardiographic study. Am J Obstet
Gynecol 177:1129–1132
8. Forster O, Hilfiker-Kleiner D, Ansari AA et al (2008) Reversal of
IFN-gamma, oxLDL and prolactin serum levels correlate with
clinical improvement in patients with peripartum cardiomyopa-
thy. Eur J Heart Fail 10:861–868
9. Hilfiker-Kleiner D, Kaminski K, Podewski E et al (2007) A
cathepsin D-cleaved 16 kDa form of prolactin mediates post-
partum cardiomyopathy. Cell 128:589–600
10. Halkein J, Tabruyn SP, Ricke-Hoch M et al (2013) MicroRNA-
146a is a therapeutic target and biomarker for peripartum car-
diomyopathy. J Clin Invest 123:2143–2154
11. Hilfiker-Kleiner D, Meyer GP, Schieffer E et al (2007) Recovery
from postpartum cardiomyopathy in 2 patients by blocking pro-
lactin release with bromocriptine. J Am Coll Cardiol
50:2354–2355
12. Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bro-
mocriptine in the treatment of acute severe peripartum cardiomy-
opathy: a proof-of-concept pilot study. Circulation 121:1465–1473
13. Sliwa K, Hilfiker-Kleiner D, Mebazaa A et al (2014) EUROb-
servational Research Programme: a worldwide registry on peri-
partum cardiomyopathy (PPCM) in conjunction with the Heart
Failure Association of the European Society of Cardiology
Working Group on PPCM. Eur J Heart Fail 16:583–591
14. McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC
guidelines for the diagnosis and treatment of acute and chronic
heart failure 2012: The task force for the diagnosis and treatment
of acute and chronic heart failure 2012 of the European Society of
Cardiology. Developed in collaboration with the Heart Failure
Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
15. Franke J, Zugck C, Wolter JS et al (2012) A decade of devel-
opments in chronic heart failure treatment: a comparison of
therapy and outcome in a secondary and tertiary hospital setting.
Clin Res Cardiol 101:1–10
16. Bo¨hm M, Borer J, Ford I et al (2013) Heart rate at baseline
influences the effect of ivabradine on cardiovascular outcomes in
chronic heart failure: analysis from the SHIFT study. Clin Res
Cardiol 102:11–22
17. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P,
Carvalho H et al (2013) Tailoring diuretic therapy in acute heart
failure: insight into early diuretic response predictors. Clin Res
Cardiol 102:745–753
18. Weil C (1986) The safety of bromocriptine in long-term use: a
review of the literature. Curr Med Res Opin 10:25–51
19. Iffy L, Lindenthal J, McArdle JJ, Ganesh V et al (1996) Severe
cerebral accidents postpartum in patients taking bromocriptine
for milk suppression. Isr J Med Sci 32:309–312
20. Hopp L, Weisse AB, Iffy L et al (1996) Acute myocardial in-
farction in a healthy mother using bromocriptine for milk sup-
pression. Can J Cardiol 12:415–418
21. Brenner B (2014) Haemostatic changes in pregnancy. Thromb
Res 114:409–414
22. Hilfiker-Kleiner D, Haghikia A, Nonhoff J et al (2015) Peripar-
tum cardiomyopathy: current management and future perspec-
tives. Eur Heart J 36:1090–1097
23. Ricke-Hoch M, Bultmann I, Stapel B et al (2014) Opposing roles
of Akt and STAT3 in the protection of the maternal heart from
peripartum stress. Cardiovasc Res 101:587–596
Clin Res Cardiol (2015) 104:911–917 917
123
